Krystal Biotech (KRYS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is KRYS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Krystal Biotech, Inc. (“Krystal Biotech” or the “Company”) (NASDAQ: KRYS). Such investors are advised to contac…

Krystal Biotech (NASDAQ: KRYS - Get Free Report) and Revolution Medicines (NASDAQ: RVMD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on th…

Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst ha…

Krystal Biotech Inc. (NASDAQ:KRYS) stock is trading lower on Monday after the company provided a third-quarter update.…

Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript…

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $2.66 per share a year ago.…

Krystal Biotech NASDAQ: KRYS reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK treatment in the United States and international markets, while also outlining updated timelines for sev…

$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell car…

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the op…

Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.…

Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with abscop…

Terra Nova Asset Management LLC purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange…

Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Vyjuvek, approved for DEB, is on track for blockbuster status in my view with $119.2m Q2 revenue and expanding…

Corient Private Wealth LP boosted its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 767.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commiss…

Hsbc Holdings PLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ: KRYS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased…

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.…

PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026,…

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

